NeuroTherapia is a Cleveland Clinic spin-off company created in 2015 to advance novel discoveries stemming from research by Drs. Mohamed Naguib and Joseph Foss. The company is focused on discovering and developing new chemical entities for the treatment of neuroinflammatory disease. The activation of immune cells, known as microglia, in the central nervous system (CNS) promote an inflammatory response that serves as a hallmark for a range of neurologic disorders such as neuropathic pain, multiple sclerosis, traumatic brain injury and Alzheimer’s disease. Our lead product, NTRX-07, is a highly selective cannabinoid type 2 (CB2) receptor agonist with demonstrated central nervous system (CNS) activity. NTRX-07 targeting of CB2 receptors on micoglia significantly reduces the expression of inflammatory agents resulting in neuronal survival and proliferation.

Pre-clinical efficacy has been established in multiple neuropathic pain models, including chemotherapy-induced peripheral neuropathy (CIPN), nerve ligation, and complex regional pain syndrome (CRPS) induced by ischemic injury. Furthermore, NTRX-07 has been shown to improve memory loss observed in Alzheimer disease rodent models. NeuroTherapia has completed IND-enabling studies with the goal of initiating first-in-man clinical studies in the first half of 2019.

For more information please access the NeuroTherapia corporate slide deck